ZFIN ID: ZDB-PUB-200612-2
Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy
Rebelo de Almeida, C., Mendes, R.V., Pezzarossa, A., Gago, J., Carvalho, C., Alves, A., Nunes, V., Brito, M.J., Cardoso, M.J., Ribeiro, J., Cardoso, F., Ferreira, M.G., Fior, R.
Date: 2020
Source: Communications biology   3: 299 (Journal)
Registered Authors: Ferreira, Miguel Godinho, Fior, Rita, Mendes, Raquel
Keywords: none
MeSH Terms:
  • Angiogenesis Inhibitors/pharmacology*
  • Animals
  • Apoptosis
  • Bevacizumab/pharmacology*
  • Cell Proliferation
  • Female
  • High-Throughput Screening Assays/methods*
  • Humans
  • Neoplasm Metastasis
  • Neovascularization, Pathologic/drug therapy*
  • Neovascularization, Pathologic/metabolism
  • Neovascularization, Pathologic/pathology
  • Triple Negative Breast Neoplasms/drug therapy*
  • Triple Negative Breast Neoplasms/metabolism
  • Triple Negative Breast Neoplasms/pathology
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays
  • Zebrafish
PubMed: 32523131 Full text @ Commun Biol
Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending on the individual tumor, anti-VEGF therapies can either block or promote metastasis. In this context, an assay able to predict individual responses prior to treatment, including the impact on metastasis would prove of great value to guide treatment options. Here we show that zebrafish xenografts are able to reveal different responses to bevacizumab in just 4 days, evaluating not only individual tumor responses but also the impact on angiogenesis and micrometastasis. Importantly, we perform proof-of-concept experiments where clinical responses in patients were compared with their matching zebrafish Patient-Derived Xenografts - zAvatars, opening the possibility of using the zebrafish model to screen bevacizumab therapy in a personalized manner.